Belite Bio rises on starting enrolment for eye disease drug

Belite Bio

22/08/2022 15:27

** Shares of drug developer Belite Bio Inc  BLTE.O  jump
~16% to $26.13 in early trade
    ** Co begins enrolling patients in a late-stage study of
experimental oral drug LBS-008 for treating a rare genetic eye
disorder called Stargardt disease that causes progressive vision
loss  urn:newsml:reuters.com:*:nGNX7p2LlY
    ** The drug has already been granted "fast track" tag by
U.S. FDA
    ** About 30,000 patients in the U.S. suffer from Stargardt
disease; there are currently no approved treatments
    ** Including session's gain, stock up ~147% since its April
IPO

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))